Ireland-based Endo International plc (OTC:ENDPQ), a specialty pharmaceutical company, announced on Monday that one of its operating companies, Par Pharmaceutical, Inc, has commenced shipping of the authorised generic (AG) version of Merck's Noxafil (posaconazole) 200mg/5mL oral suspension in the United States.
Endo Ventures Limited, a subsidiary of Endo, has signed an exclusive US supply and distribution agreement with a subsidiary of Merck & Co., Inc. of Rahway, New Jersey. The distribution agreement is intended to enable Par Pharmaceutical to introduce and distribute an authorised generic version of the product. The contract also included the authorised generic version of Noxafil delayed-release tablets, 100 mg, which was launched in 2019.
The product is a registered trademark of Merck Sharp & Dohme LLC.
Upsher-Smith launches Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%
Torrent Pharma starts shipping generic Keveyis (dichlorphenamide), 50mg tablets in US
Upsher-Smith Laboratories introduces Fluphenazine Hydrochloride Tablets
American Regent launches sulphite-free Epinephrine Injection
Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
Accord Healthcare adds Teriflunomide to oral medications range